Based on the provided legal document, here are the key points regarding the case of Novartis AG & Others vs. Union of India & Others, focusing on the patentability of the beta crystalline form of Imatinib Mesylate:

1. Legislative Context and Objectives * The Patents Act, 1970 was amended in 2005 to comply with the TRIPS Agreement, introducing product patents for pharmaceuticals. * Parliament introduced Section 3(d) specifically to prevent "evergreening" (repetitive patenting of minor changes to known substances) while encouraging genuine inventions, balancing international obligations with public health interests (!) (!) (!) (!) . * The amendment to Section 3(d) explicitly states that a "mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" is not an invention (!) . * The Explanation to Section 3(d) clarifies that salts, esters, ethers, polymorphs, etc., are considered the same substance unless they differ significantly in properties with regard to efficacy (!) .

2. Facts of the Invention * Prior Art: The drug Imatinib (free base) was invented by Jürg Zimmermann and covered under US Patent No. 5,521,184 (Zimmermann Patent), which disclosed its salts, including Imatinib Mesylate, and their therapeutic uses (!) (!) (!) (!) (!) . * Market History: The drug Gleevec (Imatinib Mesylate) was approved by the FDA and marketed globally starting in 2001, based on the Zimmermann Patent (!) (!) (!) . * Appellant's Claim: Novartis claimed the beta crystalline form of Imatinib Mesylate as a new invention. They argued it involved two stages of invention: creating the mesylate salt and then the specific beta crystal form (!) (!) . * Conduct of Appellant: Novartis previously obtained patent term extensions for the Zimmermann Patent regarding Gleevec and successfully sued competitors (e.g., NATCO Pharma) for infringement based on the Zimmermann Patent covering Imatinib Mesylate, acknowledging that the free base and its salts were part of the original patent (!) (!) (!) (!) (!) .

3. Analysis of Patentability (Section 2(1)(j) and (ja)) * Novelty and Inventive Step: The Court held that Imatinib Mesylate is a "known substance" fully disclosed in the Zimmermann Patent, including its pharmacological properties (!) (!) . * Disclosure vs. Coverage: The Court rejected the argument that "coverage" of a patent (claims) differs from "disclosure" (teaching). A patentee cannot claim a genus for which the species were not enabled or disclosed at the time of filing (!) (!) (!) . * Finding: Since Imatinib Mesylate was known and disclosed in the Zimmermann Patent, it does not qualify as a "new product" or an "invention" under Section 2(1)(j) and (ja) (!) .

4. Analysis of Patentability (Section 3(d)) * Applicability: Even if the beta crystalline form is considered a "new form" of a known substance (Imatinib Mesylate), it falls squarely under Section 3(d) because it is a polymorph of a known substance with known efficacy (!) . * Enhanced Efficacy Test: The Court emphasized that for polymorphs/salts, the test is whether there is an enhancement of therapeutic efficacy (!) (!) . * Physical Properties vs. Efficacy: Properties such as flow characteristics, thermodynamic stability, and lower hygroscopicity are beneficial for processing and storage but do not constitute "therapeutic efficacy" (!) . * Bioavailability: The appellant claimed a 30% increase in bioavailability compared to the free base. However, the Court noted: * Bioavailability is a pharmacokinetic property, distinct from pharmacodynamic efficacy (!) . * Increased bioavailability alone does not automatically prove enhanced therapeutic efficacy (!) . * The appellant failed to provide research data proving that the beta form produces superior therapeutic results on a molecular basis compared to the known substance (!) . * Comparison Error: The appellant compared the beta form to the free base, but the immediate preceding substance is Imatinib Mesylate (non-crystalline). No data was provided to show enhanced efficacy over the non-crystalline mesylate form (!) (!) .

5. Final Determination * The beta crystalline form of Imatinib Mesylate fails the test of "invention" under Section 2(1)(j) and (ja) because it is a known substance disclosed in the Zimmermann Patent (!) . * It also fails the test of "patentability" under Section 3(d) because it does not demonstrate an enhancement of the known therapeutic efficacy of Imatinib Mesylate (!) . * Held: The appeal for patent protection for the beta crystalline form of Imatinib Mesylate is dismissed (!) .